中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2013年
5期
334-337
,共4页
周黎明%郑娟%孙亦婷%赵雅云%夏爱丽
週黎明%鄭娟%孫亦婷%趙雅雲%夏愛麗
주려명%정연%손역정%조아운%하애려
子宫内膜异位症%不育,女(雌)性%亮丙瑞林%微球体%受精,体外%胚胎移植%治疗结果
子宮內膜異位癥%不育,女(雌)性%亮丙瑞林%微毬體%受精,體外%胚胎移植%治療結果
자궁내막이위증%불육,녀(자)성%량병서림%미구체%수정,체외%배태이식%치료결과
Endometriosis%Infertility,female%Leuprolide%Microspheres%Fertilization in vitro%Embryo transfer%Treatment outcome
目的 探讨醋酸亮丙瑞林微球(其他名称:贝依)治疗子宫腺肌病合并不孕的临床疗效.方法 对2011年1月1日至2012年3月31日在宁波市妇女儿童医院生殖医学中心因子宫腺肌病合并不孕接受醋酸亮丙瑞林微球超长方案超促排卵后,行体外受精-胚胎移植(IVF-ET)治疗的166例患者的166个周期(腺肌病组)的临床资料进行回顾性分析,另选取同期因输卵管因素及其他原因不孕行IVF-ET治疗的子宫正常者作为对照组,共200例患者的200个周期,观察腺肌病组经醋酸亮丙瑞林微球治疗后子宫体积的变化,并比较两组患者IVF-ET结局.结果 (1)子宫体积:腺肌病组中,经过2～6次的醋酸亮丙瑞林微球(3.75 mg/次,每28天1次)治疗后,子宫体积由治疗前的(180±73) cm3缩小至治疗后的(86±67) cm3,差异有统计学意义(P＜0.05).(2) IVF-ET结局:胚胎种植率腺肌病组为39.1％、对照组为35.8％,临床妊娠率腺肌病组为54.2％,对照组为53.7％；流产率腺肌病组为4.7％、对照组为4.2％；两组各指标分别比较,差异均无统计学意义(P＞0.05).(3)在腺肌病组中,IVF-ET治疗后妊娠失败者的受精率(67.2％,319/475)、双原核率(60.8％,289/475)及优质胚胎率(52.9％,162/306)与IVF-ET治疗后妊娠成功者[分别为74.2％(423/570)、67.7％(386/570)、62.1％(256/412)]比较,差异均有统计学意义(P＜0.05).结论 醋酸亮丙瑞林微球能显著缩小子宫腺肌病患者的子宫体积,对合并不孕行IVF-ET治疗的患者,经醋酸亮丙瑞林微球治疗后能够获得理想的助孕结局.
目的 探討醋痠亮丙瑞林微毬(其他名稱:貝依)治療子宮腺肌病閤併不孕的臨床療效.方法 對2011年1月1日至2012年3月31日在寧波市婦女兒童醫院生殖醫學中心因子宮腺肌病閤併不孕接受醋痠亮丙瑞林微毬超長方案超促排卵後,行體外受精-胚胎移植(IVF-ET)治療的166例患者的166箇週期(腺肌病組)的臨床資料進行迴顧性分析,另選取同期因輸卵管因素及其他原因不孕行IVF-ET治療的子宮正常者作為對照組,共200例患者的200箇週期,觀察腺肌病組經醋痠亮丙瑞林微毬治療後子宮體積的變化,併比較兩組患者IVF-ET結跼.結果 (1)子宮體積:腺肌病組中,經過2～6次的醋痠亮丙瑞林微毬(3.75 mg/次,每28天1次)治療後,子宮體積由治療前的(180±73) cm3縮小至治療後的(86±67) cm3,差異有統計學意義(P＜0.05).(2) IVF-ET結跼:胚胎種植率腺肌病組為39.1％、對照組為35.8％,臨床妊娠率腺肌病組為54.2％,對照組為53.7％；流產率腺肌病組為4.7％、對照組為4.2％；兩組各指標分彆比較,差異均無統計學意義(P＞0.05).(3)在腺肌病組中,IVF-ET治療後妊娠失敗者的受精率(67.2％,319/475)、雙原覈率(60.8％,289/475)及優質胚胎率(52.9％,162/306)與IVF-ET治療後妊娠成功者[分彆為74.2％(423/570)、67.7％(386/570)、62.1％(256/412)]比較,差異均有統計學意義(P＜0.05).結論 醋痠亮丙瑞林微毬能顯著縮小子宮腺肌病患者的子宮體積,對閤併不孕行IVF-ET治療的患者,經醋痠亮丙瑞林微毬治療後能夠穫得理想的助孕結跼.
목적 탐토작산량병서림미구(기타명칭:패의)치료자궁선기병합병불잉적림상료효.방법 대2011년1월1일지2012년3월31일재저파시부녀인동의원생식의학중심인자궁선기병합병불잉접수작산량병서림미구초장방안초촉배란후,행체외수정-배태이식(IVF-ET)치료적166례환자적166개주기(선기병조)적림상자료진행회고성분석,령선취동기인수란관인소급기타원인불잉행IVF-ET치료적자궁정상자작위대조조,공200례환자적200개주기,관찰선기병조경작산량병서림미구치료후자궁체적적변화,병비교량조환자IVF-ET결국.결과 (1)자궁체적:선기병조중,경과2～6차적작산량병서림미구(3.75 mg/차,매28천1차)치료후,자궁체적유치료전적(180±73) cm3축소지치료후적(86±67) cm3,차이유통계학의의(P＜0.05).(2) IVF-ET결국:배태충식솔선기병조위39.1％、대조조위35.8％,림상임신솔선기병조위54.2％,대조조위53.7％；유산솔선기병조위4.7％、대조조위4.2％；량조각지표분별비교,차이균무통계학의의(P＞0.05).(3)재선기병조중,IVF-ET치료후임신실패자적수정솔(67.2％,319/475)、쌍원핵솔(60.8％,289/475)급우질배태솔(52.9％,162/306)여IVF-ET치료후임신성공자[분별위74.2％(423/570)、67.7％(386/570)、62.1％(256/412)]비교,차이균유통계학의의(P＜0.05).결론 작산량병서림미구능현저축소자궁선기병환자적자궁체적,대합병불잉행IVF-ET치료적환자,경작산량병서림미구치료후능구획득이상적조잉결국.
Objective To study clinical efficacy of leuprorelin acetate in treatment of uterine adenomyosis with infertility.Methods From January 1,2011 to March 31,2012,166 cycles in 166 infertile patients combined with uterine adenomyosis undergoing in vitro fertilization embryo transplant (IVF-ET) with long protocol ovum induction by leuprorelin acetate in centre of medical reproduction,ningbo women and children's hospital were studied retrospectively.In the mean time,200 cycles in 200 infertile patients with tubal factors were enrolled as control group.The volume of uterus and outcome of IVF-ET were compared and studied between two groups.Results (1) Volume of uterus:in adenomyosis group,after 2-6 cycles of injecting leuprorelin acetate (3.75 mg/28 days),the mean uterine volume was shrinked from (180 ±73) cm3 to (86 ± 67) cm3 (P ＜ 0.05).(2) Outcome of IVF-ET:the rate of embryo implantation was 39.1％ in adenomyosis group and 35.8％ in control group.The rate of clinical pregnancy was 54.2％ in adenomyosis group and 53.7％ in control group.The rate of abortion was 4.7％ in adenomyosis group and 4.2％ in control group.They all did not show statistical differences (P ＞0.05).(3) In adenomyosis group,the rate of fertilization,two pronuclear (2PN) and superior embryo were 67.2％ (319/475),60.8％(289/475) and 52.9％ (162/306) in patients with failed pregnancy and 74.2％ (423/570),67.7％(386/570) and 62.1％ (256/412) in patients with successful pregnancy after IVF-ET,which reached significant difference (P ＜ 0.05).Conclusion Leuprorelin acetate could improve volume of uterine adenomyosis and outcome of pregnancy in patients undergoing IVF-ET.
